FCMR (Fc fragment of IgM receptor), also known as FAIM3 or TOSO, is a type I transmembrane sialoglycoprotein primarily expressed on B cells, T cells, and natural killer (NK) cells. Its extracellular domain shares structural homology with immunoglobulin variable regions, enabling specific binding to the Fc region of IgM antibodies . FCMR plays critical roles in immune regulation, B cell homeostasis, and anti-tumor responses, with dysregulation linked to autoimmune diseases and malignancies like chronic lymphocytic leukemia (CLL) .
FCMR regulates key immune processes:
Promotes B cell differentiation: FCMR-deficient mice exhibit reduced follicular (FO) B cells and increased peritoneal B-1a cells, suggesting a role in balancing B cell subsets .
Prevents autoimmunity: FCMR inhibits autoreactive B cells, as Fcmr−/− mice develop elevated autoantibodies, particularly in the peritoneum .
Modulates BCR signaling: Enhances tonic BCR signaling, supporting survival of marginal zone (MZ) and B-1a cells .
IgM-mediated responses: Binds pentameric and membrane-bound IgM, facilitating immune surveillance and pathogen clearance .
Anti-tumor immunity: Inhibits tumor-associated myeloid cell infiltration, as Fcmr−/− mice show increased neutrophils and monocytic dendritic cells in tumors .
Target in CLL: Elevated FCMR expression on CLL B cells suggests potential for therapeutic targeting .
Biomarker: Soluble FCMR levels may correlate with disease severity in CLL patients .
Fas apoptotic inhibitory molecule 3 (FCMR) plays a role in immune system processes. FCMR protects cells from apoptosis induced by the proteins FADD, FAS, and TNF alpha, without overexpressing apoptosis inhibitors like BCLXL or BCL2. Instead of blocking apoptotic signals downstream, FCMR activates an inhibitory pathway that prevents CASP8 activation.
Recombinant human FCMR, produced in E. coli, is a single, non-glycosylated polypeptide chain consisting of 243 amino acids (a.a 18-250), including a 10 a.a N-terminal His tag. The calculated molecular mass is 27.2 kDa.
FCMR is filtered (0.4 µm) and lyophilized from a solution of 50 mM acetate buffer, pH 4, at a concentration of 0.5 mg/ml.
To prepare a working stock solution of approximately 0.5 mg/ml, add 0.1 M acetate buffer (pH 4) to the lyophilized pellet and allow it to dissolve completely. Please note that the solubility of this antigen is limited at higher concentrations.
Purity is determined to be greater than 95.0% by SDS-PAGE analysis.
Fas apoptotic inhibitory molecule 3, IgM Fc fragment receptor, Regulator of Fas-induced apoptosis Toso, FAIM3, TOSO.
MKHHHHHHAS RILPEVKVEG ELGGSVTIKC PLPEMHVRIY LCREMAGSGT CGTVVSTTNF IKAEYKGRVT LKQYPRKNLF LVEVTQLTES DSGVYACGAG MNTDRGKTQK VTLNVHSEYE PSWEEQPMPE TPKWFHLPYL FQMPAYASSS KFVTRVTTPA QRGKVPPVHH SSPTTQITHR PRVSRASSVA GDKPRTFLPS TTASKISALE GLLKPQTPSY NHHTRLHRQR ALDYGSQSGR EGQ.
FCMR (Fc receptor for IgM, also known as FcμR) is a unique receptor that specifically binds to IgM antibodies. Unlike other Fc receptors that primarily associate with myeloid cells, FCMR is preferentially expressed by cells of the adaptive immune system and represents the only constitutively expressed Fc receptor on human T cells .
This selectivity suggests specialized functional roles for FCMR in IgM-mediated immune responses, though efforts to fully characterize these functions have been complicated by species-specific expression patterns between humans and mice.
The expression pattern of FCMR in humans differs significantly from that in mice, contributing to challenges in deciphering its normal physiological functions. In humans, FCMR expression occurs across multiple lymphocyte populations:
B cells
NK cells
T cells
Notably, FCMR stands as the only constitutively expressed Fc receptor on human T cells, suggesting a potentially important role in T cell biology . This broad distribution across adaptive immune cell populations contrasts with mice, where FCMR expression is primarily restricted to B cells .
Recent cryo-electron microscopy (cryo-EM) studies have revealed detailed insights into how FCMR interacts with IgM. The binding interface involves three complementarity-determining region (CDR) loops in the FCMR Ig-like domain that interact specifically with the Cμ4 domains of IgM .
Key structural elements of this interaction include:
CDR loops: CDR1 (purple), CDR2 (green), and CDR3 (blue) loops of FCMR form specific contacts with two adjacent Cμ4 domains within an IgM subunit
Hydrogen bonding network: Multiple hydrogen bonds stabilize the FCMR-IgM interface, some of which are conserved with pIgR-D1/IgM interactions while others are unique to FCMR
Extended interactions: The CDR3 loop of FCMR makes additional contacts with neighboring Cμ4 domains and the tailpiece of IgM in certain binding configurations
Methodologically, these structural insights were obtained using cryo-EM analysis of the FcμR/IgM-Fc complex with resolutions ranging from 3.2-5.4 Å, enabling detailed visualization of the binding interface and identification of key interacting residues .
Structural analysis has identified eight binding sites for the human FCMR Ig domain on the IgM pentamer, distributed across both the front and back faces of the molecule . This arrangement includes:
| Face | Binding Sites | Subunits | Notes |
|---|---|---|---|
| Front | 4 | Fcμ1-Fcμ4 | Front of Fcμ5 blocked by J chain hairpin-1 loop |
| Back | 4 | Fcμ2-Fcμ5 | Back of Fcμ1 blocked by J chain hairpin-2 loop |
The presence of the J chain appears to block potential binding sites at the front of Fcμ5 and the back of Fcμ1, reducing the theoretical maximum of ten binding sites to eight . Importantly, one of these eight binding sites overlaps with receptor binding sites for other molecules, suggesting potential competitive binding mechanisms that may regulate FCMR function .
Only the Ig-like domain of FCMR appears ordered in the structural analysis, indicating flexibility of the stalk region mediating membrane attachment. This flexibility likely facilitates dynamic interactions in the cellular context .
Contrary to previous assumptions, recent research has uncovered that cell density rather than IgM abundance is the primary factor affecting FCMR display on human lymphocytes . Earlier studies had suggested that ligand-induced internalization by serum IgM contributed to low baseline FCMR expression, leading to recommendations for preincubation in IgM-free culture medium when studying FCMR.
Cell-surface FCMR expression was surprisingly unaffected by IgM abundance
FCMR was significantly downregulated in high-cell density cultures through an as-yet undefined mechanism
Ex vivo processing of whole blood decreased surface FCMR detection
These findings challenge previous methodological approaches and suggest that FCMR expression is likely greater on circulating lymphocytes than previously appreciated. Researchers should therefore consider cell density as a critical variable when designing experiments to study FCMR expression and function.
Sample processing methodologies significantly impact the measurement of FCMR expression, with important implications for experimental design and data interpretation . Researchers should consider the following methodological factors:
| Processing Factor | Impact on FCMR | Recommendation |
|---|---|---|
| Whole blood ex vivo processing | Decreases surface FCMR detection | Minimize processing time; consider direct whole blood analysis |
| Cell isolation procedures | High-density preparations reduce FCMR expression | Control and document cell densities; avoid overcrowding |
| Time between collection and analysis | Longer intervals may alter expression profiles | Process samples promptly; establish consistent protocols |
| Culture conditions | Cell proliferation can affect density and FCMR levels | Maintain standardized cell concentrations across experiments |
These findings prompt new predictions about when and where FCMR might be available for functional interactions in vivo, suggesting that previous studies may have underestimated the physiological expression levels and potential functional significance of this receptor .
To effectively investigate the specificity of FCMR for IgM over other antibody isotypes, researchers should employ multiple complementary methodological approaches:
Structural analysis techniques:
Mutagenesis approaches:
Site-directed mutagenesis of key residues in the CDR loops of FCMR identified from structural studies
Creation of chimeric receptors exchanging domains between FCMR and pIgR to identify specificity-determining regions
CRISPR-Cas9 gene editing to introduce precise mutations in endogenous FCMR
Binding assays:
Surface plasmon resonance to quantify binding kinetics and affinity constants
Bio-layer interferometry with immobilized IgM versus other antibody isotypes
Cell-based binding assays using flow cytometry with fluorescently labeled antibodies
These methodologies should be applied systematically to build a comprehensive understanding of the molecular basis for FCMR's IgM specificity, potentially leading to therapeutic applications targeting this receptor .
The presence of eight binding sites for FCMR on the IgM pentamer has significant functional implications that researchers can investigate through several methodological approaches:
Avidity effects:
The multivalent binding arrangement likely enables high-avidity interactions despite potentially moderate affinity of individual binding events
This may explain FCMR's effectiveness in capturing IgM at physiological concentrations
Signaling complexity:
Multiple binding sites could enable complex signaling patterns when FCMR engages with IgM
Partial occupancy versus full occupancy might trigger different downstream pathways
Competitive binding mechanisms:
Methodologically, researchers can investigate these functional implications through:
Single-molecule imaging techniques to visualize sequential binding events
Engineered IgM variants with selective binding site mutations
Quantitative signaling assays comparing responses to IgM with different binding site availability
These approaches would help elucidate how the structural arrangement of multiple binding sites contributes to FCMR's biological functions in different immunological contexts .
For accurate measurement of FCMR expression on human lymphocytes, researchers should implement the following methodological strategies:
Fresh sample analysis:
When possible, analyze FCMR expression directly from fresh whole blood samples
If using isolated cells, minimize processing time and maintain appropriate cell separation
Document all processing steps and timing for reproducibility
Cell density control:
Standardize and report cell densities in all experiments
Use low-density cultures when higher FCMR expression is required for detection
Include appropriate controls at multiple density points to calibrate measurements
Complementary detection methods:
Flow cytometry using validated anti-FCMR antibodies
RT-qPCR for FCMR mRNA quantification to complement protein expression data
Immunofluorescence microscopy to assess spatial distribution on cell surfaces
Comparative baseline establishment:
Include timepoint zero measurements immediately after collection
Compare expression levels between whole blood, freshly isolated cells, and cultured cells
Document changes during experimental manipulation to understand FCMR dynamics
These methodological considerations are essential for generating reliable and physiologically relevant data on FCMR expression, particularly given the emerging understanding that traditional approaches may underestimate actual expression levels .
Given the significant impact of cell density on FCMR expression, researchers should implement specific protocols to manage this variable:
Standardized density controls:
Establish and document optimal cell density ranges for FCMR studies
Ensure consistent seeding densities across experimental replicates
Include density gradients as internal controls when appropriate
Culture system considerations:
Use culture vessels with consistent surface area-to-volume ratios
Implement gentle agitation systems to prevent localized high-density regions
Consider three-dimensional culture systems that better mimic physiological spacing
Temporal monitoring:
Track cell proliferation throughout experiments
Adjust seeding densities based on expected proliferation rates
Establish consistent timepoints for analysis relative to density changes
Physiological relevance:
Consider how experimental densities compare to those in various lymphoid tissues
Investigate density-dependent regulation as a potential physiological mechanism
Design experiments that reflect relevant in vivo cellular environments
By carefully controlling cell density as an experimental variable, researchers can generate more consistent and physiologically relevant data on FCMR expression and function, leading to better understanding of its role in immune regulation .
The Fc fragment of IgM receptor, also known as FcμR, is a crucial component of the immune system. It is the newest member of the Fc receptor family, having been identified in 2009 . This receptor is uniquely expressed by lymphocytes, which suggests it has distinct functions compared to other Fc receptors that are expressed by various immune and non-hematopoietic cells .
The FcμR is a membrane-bound receptor that specifically binds to the Fc region of Immunoglobulin M (IgM) antibodies. IgM is the first antibody to emerge during phylogeny, ontogeny, and immune responses, serving as a first line of defense . The Fc region of IgM contains three heavy chain constant domains (Cμ2-Cμ4) in each polypeptide chain . The interaction between FcμR and the Fc region of IgM is critical for mediating various immune responses.
FcμR plays a significant role in regulating B cell tolerance. Studies involving FcμR-deficient mice have shown a propensity to produce autoantibodies of both IgM and IgG isotypes, indicating a regulatory function of FcμR in maintaining immune homeostasis . Additionally, FcμR is involved in protecting cells from apoptosis induced by proteins such as FADD, FAS, and TNF alpha, without overexpressing inhibitors of apoptosis like BCLXL or BCL2 .
Elevated levels of a soluble FcμR isoform have been observed in serum samples from patients with chronic lymphocytic leukemia and antibody-mediated autoimmune disorders . This suggests that persistent B cell receptor stimulation can lead to increased levels of soluble FcμR, which may have implications in the pathogenesis of these diseases.
Understanding the role of FcμR in immune regulation opens up potential therapeutic avenues. Targeting FcμR could be a strategy for modulating immune responses in autoimmune diseases and certain types of leukemia. Further research is needed to fully elucidate the mechanisms by which FcμR functions and its potential as a therapeutic target.